论文部分内容阅读
新药研发在我国一直处于一个“不怎么好”的状况,以致于创新药物在中国少之又少。作为国际公认的少数几个创新化学药物之一的青蒿素,却由于知识产权保护不力,导致了每年2至3亿美元的出口损失。我们可以说当时的环境不允许我们搞好知识产权的保护,可是在知识产权保护法规日趋完善的今天我们看到的仍然是大批量的低水平重复生产。为什么我们国家真正的新药如此之少?对此记者采访了中国医学科学院药物研究所副所长吴松。
New drug research and development in our country has been in a “not very good” condition, so that innovative drugs in China with very few. Artemisinin, one of the few internationally recognized innovative chemical drugs, has caused an annual export loss of between 200 and 300 million U.S. dollars due to the poor protection of intellectual property rights. We can say that the current environment does not allow us to improve the protection of intellectual property rights. However, as the laws on intellectual property protection are getting better day by day, we still see large quantities of low-level repeated production. Why so few new drugs in our country? This reporter interviewed the Chinese Academy of Medical Sciences Institute of Materia Medica, deputy director of Wu Song.